{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?page=2&sponsor=Daiichi+Sankyo", "query": { "sponsor": "Daiichi Sankyo", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=1&sponsor=Daiichi+Sankyo&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-07T10:19:18.965Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00151762", "title": "Long-Term Study of Safety and Efficacy of WelChol® as an Additional Therapy in Patients With Type 2 Diabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Type 2 Diabetes" ], "interventions": [ { "name": "Colesevelam hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 780, "start_date": "2004-12", "completion_date": "2007-07", "has_results": false, "last_update_posted_date": "2008-01-09", "last_synced_at": "2026-06-07T10:19:18.965Z", "location_count": 62, "location_summary": "Birmingham, Alabama • Tuscumbia, Alabama • Jonesboro, Arkansas + 59 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tuscumbia", "state": "Alabama" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Searcy", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00151762" }, { "nct_id": "NCT07205822", "title": "A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Dato-DXd", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2025-10-30", "completion_date": "2028-02-02", "has_results": false, "last_update_posted_date": "2026-05-12", "last_synced_at": "2026-06-07T10:19:18.965Z", "location_count": 6, "location_summary": "Largo, Florida • Fort Wayne, Indiana • Omaha, Nebraska + 3 more", "locations": [ { "city": "Largo", "state": "Florida" }, { "city": "Fort Wayne", "state": "Indiana" }, { "city": "Omaha", "state": "Nebraska" }, { "city": "New York", "state": "New York" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07205822" }, { "nct_id": "NCT00004866", "title": "DX-8951f in Treating Women Who Have Advanced or Recurrent Cancer of the Cervix", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cervical Cancer" ], "interventions": [ { "name": "exatecan mesylate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": null, "start_date": "2000-01", "completion_date": "2003-09", "has_results": false, "last_update_posted_date": "2012-05-16", "last_synced_at": "2026-06-07T10:19:18.965Z", "location_count": 6, "location_summary": "New York, New York • The Bronx, New York • Toledo, Ohio + 3 more", "locations": [ { "city": "New York", "state": "New York" }, { "city": "The Bronx", "state": "New York" }, { "city": "Toledo", "state": "Ohio" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004866" }, { "nct_id": "NCT05489211", "title": "Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Endometrial Cancer", "Gastric Cancer", "Metastatic Castration-resistant Prostate Cancer", "Ovarian Cancer", "Colorectal Cancer", "Urothelial Cancer", "Biliary Tract Cancer" ], "interventions": [ { "name": "Datopotamab deruxtecan (Dato-DXd)", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "5-Fluorouracil", "type": "DRUG" }, { "name": "Volrustomig", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Rilvegostomig", "type": "DRUG" }, { "name": "Prednisone/ prednisolone", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 454, "start_date": "2022-09-06", "completion_date": "2027-10-01", "has_results": false, "last_update_posted_date": "2026-03-19", "last_synced_at": "2026-06-07T10:19:18.965Z", "location_count": 18, "location_summary": "Los Angeles, California • San Diego, California • Santa Rosa, California + 13 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Santa Rosa", "state": "California" }, { "city": "Muncie", "state": "Indiana" }, { "city": "Kansas City", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05489211" }, { "nct_id": "NCT05795101", "title": "TRUDI: TDXD+Durva in HER2+/Low IBC", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Invasive Breast Cancer", "Inflammatory Breast Cancer Stage III", "HER2-positive Breast Cancer", "HER2 Low Breast Adenocarcinoma", "Breast Cancer" ], "interventions": [ { "name": "Trastuzumab deruxtecan", "type": "DRUG" }, { "name": "Durvalumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Filipa Lynce, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 63, "start_date": "2023-05-04", "completion_date": "2032-12-01", "has_results": false, "last_update_posted_date": "2025-09-19", "last_synced_at": "2026-06-07T10:19:18.965Z", "location_count": 3, "location_summary": "Boston, Massachusetts • Houston, Texas", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05795101" }, { "nct_id": "NCT02647320", "title": "12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "Sitagliptin 100 mg", "type": "DRUG" }, { "name": "DS-8500a 25mg", "type": "DRUG" }, { "name": "Placebo Tablet", "type": "DRUG" }, { "name": "Placebo Capsule", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 298, "start_date": "2016-01", "completion_date": "2017-01-31", "has_results": true, "last_update_posted_date": "2019-02-25", "last_synced_at": "2026-06-07T10:19:18.965Z", "location_count": 48, "location_summary": "Birmingham, Alabama • Litchfield Park, Arizona • Tempe, Arizona + 41 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Litchfield Park", "state": "Arizona" }, { "city": "Tempe", "state": "Arizona" }, { "city": "Anaheim", "state": "California" }, { "city": "Chino", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02647320" }, { "nct_id": "NCT00290940", "title": "Evaluation of Glucose Lowering Effect, Safety and Tolerability of CS-917", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "CS-917", "type": "DRUG" }, { "name": "metformin hydrochloride", "type": "DRUG" }, { "name": "pioglitazone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 400, "start_date": "2006-01", "completion_date": "2007-04", "has_results": false, "last_update_posted_date": "2007-09-11", "last_synced_at": "2026-06-07T10:19:18.965Z", "location_count": 66, "location_summary": "Birmingham, Alabama • Northport, Alabama • Mesa, Arizona + 62 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Northport", "state": "Alabama" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tempe", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00290940" }, { "nct_id": "NCT03384940", "title": "DS-8201a in Human Epidermal Growth Factor Receptor2 (HER2)-Expressing Colorectal Cancer (DESTINY-CRC01)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Neoplasm" ], "interventions": [ { "name": "DS-8201a", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo Co., Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 86, "start_date": "2018-02-23", "completion_date": "2020-11-10", "has_results": true, "last_update_posted_date": "2021-10-18", "last_synced_at": "2026-06-07T10:19:18.965Z", "location_count": 9, "location_summary": "Duarte, California • Los Angeles, California • Santa Monica, California + 6 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT03384940" }, { "nct_id": "NCT05629585", "title": "A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Dato-DXd", "type": "DRUG" }, { "name": "Durvalumab", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 1174, "start_date": "2022-11-28", "completion_date": "2030-01-30", "has_results": false, "last_update_posted_date": "2026-03-18", "last_synced_at": "2026-06-07T10:19:18.965Z", "location_count": 88, "location_summary": "Gilbert, Arizona • Tucson, Arizona • Hot Springs, Arkansas + 70 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05629585" }, { "nct_id": "NCT01496885", "title": "Observational Study to Evaluate the Simplified-STroke REhabilitation Assessment of Movement (S-STREAM) Scale in Subjects Who Have Experienced a Nonhemorrhagic Ischemic Stroke", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Nonhemorrhagic Ischemic Stroke", "Motor Function" ], "interventions": [ { "name": "Observational study", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "21 Years to 85 Years" }, "enrollment_count": 120, "start_date": "2012-01-18", "completion_date": "2013-05-22", "has_results": true, "last_update_posted_date": "2021-02-03", "last_synced_at": "2026-06-07T10:19:18.965Z", "location_count": 22, "location_summary": "Newport Beach, California • Englewood, Colorado • Lawrenceville, Georgia + 18 more", "locations": [ { "city": "Newport Beach", "state": "California" }, { "city": "Englewood", "state": "Colorado" }, { "city": "Lawrenceville", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Des Moines", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT01496885" } ] }